Cancer a concern for BMS/AstraZeneca drug, but liver injury could be FDA panel focus
This article was originally published in Scrip
Executive Summary
While analysts expected the US FDA to hone in on the nine breast and nine bladder cancers in study participants who received Bristol-Myers Squibb's and AstraZeneca's investigational Type II diabetes drug dapagliflozin, the agency's concerns over drug-induced liver injury (DILI) came as a surprise to Wall Street.